United Therapeutics Corporation (UTHR) Up 14.7% — Time to Strike?
United Therapeutics Corporation (UTHR) is surging on Wednesday, last changing hands at $551.98 on the NASDAQ. That is a $70.51 gain from the prior close of $481.47 and one of the sharpest single-session advances in the name this year. The rally lifts the stock roughly 34.9% above the bottom of its 52-week range at $409.07 and within about 9.4% of its 52-week high of $609.35. A retest of that upper bound is now a realistic near-term conversation.
Volume confirms the conviction behind the move. Roughly 1.89 million shares have traded so far against a 90-day average of about 559,000, which is nearly 3.4 times normal turnover with the session still open.
Why United Therapeutics Corporation Price is Moving Higher
The lead catalyst is regulatory. On September 30, the FDA had accepted United Therapeutics' supplemental application for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF), with the review expected to conclude around April 2027. The stakes are significant. Approval would position Tyvaso as the first inhaled antifibrotic treatment for IPF and extend the franchise well beyond its pulmonary arterial hypertension base into a much larger patient population. The filing rests on positive results from two Phase 3 trials, TETON-1 and TETON-2. That two-study foundation gives investors a clear, dated milestone to price in rather than a speculative pipeline hope.
Capital return added fuel. United Therapeutics entered an accelerated share repurchase agreement covering the remaining $477.6 million of its authorized $2.0 billion buyback. Pulling that capital forward concentrates the per-share earnings benefit and signals management's confidence that the stock was undervalued at recent levels. The timing matters because the shares came into this week under pressure. Goldman Sachs initiated coverage on September 24, with a Sell rating and a $321 price target, a call that weighed on the stock and set up today's forceful reversal. The broader group offers no explanation for the move. Eli Lilly and Company (LLY) is up just 0.13% and AbbVie Inc. (ABBV) is ahead 0.17%, so this rally belongs to United Therapeutics alone.
The fundamentals give the rally a sturdy base. The company carries trailing EPS of $27.95, and the stock trades at a P/E of 17.22 even after today's jump, with a forward P/E of 17.37. That is a modest multiple for a business with a potential new indication on the regulatory calendar. Revenue was $783.3 million for the quarter ended June 30, 2026, up 0.2% from $781.5 million in the March quarter. That steady top line is the foundation the IPF opportunity would build on.
What is the United Therapeutics Corporation Rating - Should I Buy?
Weiss Ratings assigns UTHR a B- rating. The rating was upgraded on 5/14/2024. Current recommendation is Buy. That upgrade has held for more than two years, and today's pipeline and buyback news reinforces the case behind it: a highly profitable specialty drugmaker with a clear path to extending its core franchise.
The strength sits in the fundamentals, where United Therapeutics is rated Excellent on the Growth, Efficiency, and Solvency indices. The Growth Index rating looks past a 1.92% dip in trailing revenue to the company's earnings power. Trailing EPS stands at $27.95, and a late-stage program in IPF could open a market substantially larger than the pulmonary arterial hypertension niche the company already dominates. The Excellent Efficiency Index rating is backed by a 41.55% profit margin and a 19.32% ROE. Those are exceptional figures for a drug developer that also funds research into organ manufacturing, and they show how much of each treprostinil dollar reaches the bottom line. The Excellent Solvency rating shows up in the capital-return program itself. A company that can commit the final $477.6 million of a $2.0 billion authorization through an accelerated repurchase is operating from a position of genuine balance-sheet strength.
Where the picture becomes more nuanced is in the market-based measures. United Therapeutics is rated Fair on both the Total Return Index and the Volatility Index. The stock has traveled a wide 52-week range between $409.07 and $609.35, and it still trades below that high despite today's advance. This month alone shows the swings. Goldman Sachs' Sell initiation pushed the shares lower, then the FDA acceptance and accelerated buyback drove a 14.65% one-day reversal. Moves that sharp in both directions explain why the Volatility Index is not rated higher. They are also what caps the overall rating at B- rather than a full B.
Within the Health Care sector, United Therapeutics is on par with AbbVie Inc. (ABBV, B-). It sits a notch below Eli Lilly and Company (LLY, B), Amgen Inc. (AMGN, B), and Vertex Pharmaceuticals Incorporated (VRTX, B). The gap is small, and UTHR's P/E of 17.22 alongside Excellent ratings on all three fundamental indices makes a strong case that it offers comparable quality at a more approachable valuation.
About United Therapeutics Corporation
United Therapeutics Corporation (UTHR) is a Health Care company focused on therapies for chronic and life-threatening conditions, with a particular concentration in pulmonary arterial hypertension (PAH). Founded in 1996 by Martine Rothblatt and organized as a public benefit corporation, the company built its franchise around treprostinil, a prostacyclin analog it delivers through several routes of administration. Tyvaso, an inhaled treprostinil solution, and its dry-powder counterpart Tyvaso DPI anchor the portfolio. They sit alongside Remodulin, an injectable treprostinil given subcutaneously or intravenously, and Orenitram, an extended-release oral tablet. The company also markets Adcirca, a tadalafil tablet for PAH, and Unituxin, an antibody therapy for high-risk pediatric neuroblastoma.
The company's competitive advantage lies in its depth within a single molecule and disease area. By offering treprostinil across inhaled, injectable, and oral formulations, United Therapeutics can serve patients at different stages of disease and treatment preference. That breadth builds physician familiarity and patient retention that narrower competitors struggle to match. The planned expansion of nebulized Tyvaso into idiopathic pulmonary fibrosis would carry that inhaled-delivery expertise into a new, broader lung-disease market.
Beyond its commercial drugs, United Therapeutics invests in longer-horizon programs aimed at addressing the shortage of transplantable organs. These include xenotransplantation, meaning organs from genetically modified pigs, and ex-vivo lung perfusion technology that refurbishes donor lungs for transplant. These efforts set the company apart from traditional specialty pharmaceutical peers. The high-margin treprostinil business funds the research while also supplying the cash flow behind its substantial share repurchase activity.
Investor Outlook
United Therapeutics Corporation (UTHR) carries a Weiss Rating of B- (Buy). The FDA's acceptance of the nebulized Tyvaso filing in IPF gives the stock a defined catalyst ahead, while the $477.6 million accelerated repurchase supports per-share earnings in the meantime. Investors should track progress toward the review decision expected around April 2027, the stock's approach to its $609.35 52-week high, and whether quarterly revenue builds on the $783.3 million posted for the June 2026 quarter. See full rankings of all B- rated Health Care stocks inside the Weiss Stock Screener.
--